Wobble Genomics

Wobble Genomics is a biotechnology company providing an RNA sequencing platform for the discovery of novel nucleic acid biomarkers to advance precision medicine, particularly in cancer. The company uses full-length RNA sequencing from blood to detect biomarkers that have the potential to revolutionize cancer medicine, enabling cancer to be seen in ways not previously possible. Wobble Genomics’ technology includes Level-Up, a cDNA normalization technology that allows non-targeted sequencing efficiency for biomarker discovery, and TAMA, an RNA sequencing bioinformatics software for gene detection. The platform supports applications including biomarker discovery and development, protein analysis, cancer regulatory pathways and immune activity, transcriptome discovery, and fusion gene identification. Founded in 2020 and headquartered at the Roslin Innovation Centre, Easter Bush Campus, Midlothian, United Kingdom, the company has raised approximately $12.5 million in Series A funding. Investors include Eos Advisory, IQ Capital, Mercia, DeepTech Ventures, Old College Capital, BGFG, and Edinburgh Technology. The company has approximately 19 employees.